Anavex Life Sciences Corp... (AVXL)
NASDAQ: AVXL
· Real-Time Price · USD
9.89
0.04 (0.41%)
At close: Oct 09, 2025, 10:57 AM
0.41% (1D)
| Bid | 9.88 |
| Market Cap | 849.49M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.93M |
| EPS (ttm) | -0.57 |
| PE Ratio (ttm) | -17.35 |
| Forward PE | 4.13 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 9.91 |
| Volume | 310,115 |
| Avg. Volume (20D) | 1,291,231.1 |
| Open | 9.83 |
| Previous Close | 9.85 |
| Day's Range | 9.73 - 9.94 |
| 52-Week Range | 5.03 - 14.44 |
| Beta | 0.83 |
| Ex-Dividend Date | n/a |
About AVXL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AVXL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AVXL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 weeks ago
+9.73%
Anavex Life Sciences shares are trading higher. Th...
Unlock content with
Pro Subscription
8 months ago
+8.21%
Anavex Life Sciences shares are trading higher after the company revealed the publication of its peer-reviewed oral blarcamesine Phase IIb/III data in the Journal of Prevention of Alzheimer's Disease.
1 month ago · seekingalpha.com
Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call TranscriptAnavex Life Sciences Corp. (NASDAQ:AVXL ) Q3 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Christopher U. Missling - President, CEO, Secretary & Director Clint Tomlinso...
